… bile, and as such patients with impaired hepatic function were … dosing in patients with cancer
with hepatic dysfunction was … for pharmacologic analysis.) during the conduct of the study. …

… Organ Dysfunction Working Group's hepatic impairment categorization and two drug-induced
liver … scores of hepatic function, such as the Model for End-Stage Liver Disease or Child–…

… very poor and alteration of liver function is … National Cancer Institute Organ Dysfunction
Working Group conducted a phase I study on the pharmacokinetics of oxaliplatin in patients …

… In our patient population low serum albumin and liver function classification as … of hepatic
impairment. A SWOG early therapeutics committee and NCI organ dysfunction working group …

… of liver function in patients with different cancers. The severity of … the organ dysfunction,
pharmacokinetics and pharmacology … such as the NCI Organ Dysfunction Working Group (NCI-…

… are often excluded because impaired renal function might be … this study, we show that
oncology organ dysfunction studies … of the drug or pharmacologically active metabolite or is a …

… oxaliplatin (CAPOX) is a standard treatment for resected colon cancer; however, in patients
with moderate renal impairment, … National Cancer Institute Organ Dysfunction Working Group …

… kinases to become pharmacologically active. Subsequently, it … Monitoring of liver function
during treatment is recommended … and oxaliplatin could be used in the context of patients with …

… primarily metabolized by the liver, they may have pharmacologically active (eg morphine/…
) to dose stratify patients with impaired kidney function being administered oxaliplatin, it was …

… W, Grem JL; National Cancer Institute Organ Dysfunction Working Group Study: Dose-escalating
and pharmacological study of oxaliplatin in adult cancer patients with impaired renal …